Data tables for the Eliminating cervical cancer in Canada digital report
Access the data tables and footnotes for the following pages:
- Cervical cancer rates in Canada
- Modelling projections for eliminating cervical cancer
- Progress on HPV vaccination in Canada
- Current state of cervical screening
- HPV primary screening progress
- HPV positive screen follow-up
Cervical cancer rates in Canada
Age-standardized incidence rate (per 100,000) for cervical cancer, Canada†, 1994 to 2022
| Year | Incidence |
|---|---|
| 1994 | 11.1 |
| 1995 | 10.8 |
| 1996 | 10.8 |
| 1997 | 10 |
| 1998 | 9.6 |
| 1999 | 9.8 |
| 2000 | 9.4 |
| 2001 | 9.4 |
| 2002 | 9.1 |
| 2003 | 8.9 |
| 2004 | 8.7 |
| 2005 | 8.2 |
| 2006 | 8.4 |
| 2007 | 8.7 |
| 2008 | 8.4 |
| 2009 | 8.6 |
| 2010 | 8.8 |
| 2011 | 8.8 |
| 2012 | 8.7 |
| 2013 | 7.9 |
| 2014 | 8.0 |
| 2015 | 7.8 |
| 2016 | 8.3 |
| 2017 | 8.2 |
| 2018 | 8.5 |
| 2019 | 8.9 |
| 2020 | 8.2 |
| 2021 | 7.9 |
| 2022 | 8.7 |
† Based on trends in age-standardized incidence rates per 100,000 for cervical cancer (females only) from 1994 to 2022, Canada. Quebec incidence data was carried forward from 2017 and Nova Scotia incidence data was carried forward from 2019. Rates are age-standardized to the 2021 Canadian standard population. The COVID-19 pandemic impacted routine cervical cancer screening in 2020 and may have affected incidence rates from 2020-21.
Data source: Canadian Cancer Registry, Statistics Canada
Age-standardized incidence rate (per 100,000) for cervical cancer, by jurisdiction†, 2020 and 2022
| Jurisdiction | 2020 incidence rate | 2022 incidence rate |
|---|---|---|
| Canada | 8.2 | 8.7 |
| British Columbia | 8.3 | 9.2 |
| Alberta | 8.5 | 8.7 |
| Saskatchewan | 9.5 | 11.8 |
| Manitoba | 8.9 | 9.6 |
| Ontario | 7.7 | 8.2 |
| Quebec | 8.3 | 8.2 |
| New Brunswick | 9.1 | 9.5 |
| Nova Scotia | 11.1 | 10.7 |
| Prince Edward Island | 10.3 | 4.4 |
| Newfoundland and Labrador | 7.3 | 8.6 |
†Data for Canada includes all jurisdictions. Quebec incidence data was carried forward from 2017 and Nova Scotia data was carried forward from 2019.
Rates are age-standardized to the 2021 Canadian standard population.
Cervical cancer cases in Northwest Territories, Yukon and Nunavut were suppressed due to small numbers.
The COVID-19 pandemic impacted routine cervical cancer screening in 2020 and may have affected incidence rates for 2020.
Data source: Canadian Cancer Registry, Statistics Canada.
Age-standardized incidence rate (per 100,000) for cervical cancer, by neighbourhood income quintile and geographic location, Canada†, 2020 to 2022 combined
| Stratification | Classification | Age-standardized incidence rate (per 100,000) |
|---|---|---|
| Neighbourhood income quintile | Q1 – lowest | 9.3 |
| Neighbourhood income quintile | Q2 | 8.7 |
| Neighbourhood income quintile | Q3 | 7.5 |
| Neighbourhood income quintile | Q4 | 8.1 |
| Neighbourhood income quintile | Q5 – highest | 7.6 |
| Location | Rural | 9.2 |
| Location | Urban | 8.1 |
†Data for Canada includes all provinces/territories except Quebec and Nova Scotia. Rates are standardized to the 2021 Canadian standard population.
The COVID-19 pandemic impacted routine cervical cancer screening in 2020 and may have affected incidence rates from 2020-21.
Data source: Canadian Cancer Registry, Statistics Canada.
Modelling projections for eliminating cervical cancer
Projected age-standardized incidence rate (per 100,000 females) for cervical cancer by level of HPV vaccination uptake* and level and type of cervical screening, 2015-2050
| Year | Status quo vaccination (70%) and screening (70% Pap) | Status quo vaccination (70%), switch to HPV screening (70%) | ECC Action Plan goal: 90% vaccination, 90% HPV screening |
|---|---|---|---|
| 2015 | 6.87 | 6.87 | 6.87 |
| 2016 | 6.92 | 6.92 | 6.92 |
| 2017 | 6.74 | 6.74 | 6.74 |
| 2018 | 7.06 | 7.06 | 7.06 |
| 2019 | 6.91 | 6.91 | 6.91 |
| 2020 | 6.66 | 6.66 | 6.66 |
| 2021 | 7.17 | 7.17 | 7.17 |
| 2022 | 6.70 | 6.70 | 6.70 |
| 2023 | 6.36 | 6.36 | 6.36 |
| 2024 | 6.58 | 6.58 | 6.58 |
| 2025 | 6.34 | 6.53 | 6.76 |
| 2026 | 5.98 | 6.05 | 6.21 |
| 2027 | 6.31 | 6.28 | 6.28 |
| 2028 | 5.92 | 5.18 | 4.72 |
| 2029 | 5.74 | 4.84 | 4.43 |
| 2030 | 5.83 | 4.82 | 4.26 |
| 2031 | 5.43 | 4.13 | 3.67 |
| 2032 | 5.37 | 4.16 | 3.68 |
| 2033 | 5.35 | 4.02 | 3.50 |
| 2034 | 5.13 | 3.79 | 3.31 |
| 2035 | 4.97 | 3.65 | 3.19 |
| 2036 | 5.05 | 3.68 | 3.18 |
| 2037 | 4.75 | 3.48 | 3.07 |
| 2038 | 4.75 | 3.46 | 3.02 |
| 2039 | 4.77 | 3.50 | 3.05 |
| 2040 | 4.59 | 3.29 | 2.85 |
| 2041 | 4.44 | 3.16 | 2.68 |
| 2042 | 4.34 | 3.07 | 2.67 |
| 2043 | 4.30 | 3.07 | 2.67 |
| 2044 | 4.11 | 3.03 | 2.55 |
| 2045 | 4.15 | 3.02 | 2.57 |
| 2046 | 4.03 | 3.03 | 2.51 |
| 2047 | 3.95 | 2.85 | 2.44 |
| 2048 | 3.91 | 2.83 | 2.39 |
| 2049 | 3.71 | 2.79 | 2.29 |
| 2050 | 3.68 | 2.80 | 2.25 |
| 2051 | 3.64 | 2.74 | 2.27 |
Oncosim modelling projections were run in 2025 using the World Health Organization’s World Standard Population.
* HPV vaccination uptake rates are based on full vaccination against HPV, based on NACI immunization guidelines.
Projected age-standardized incidence rate (per 100,000 females) for cervical cancer by HPV screening implementation year, 2015-2050
| Year | Status quo vaccination (70%) and screening (70% Pap) | Status quo vaccination (70%), switch to HPV screening (70%) | ECC Action Plan goal: 90% vaccination, 90% HPV screening | Status quo vaccination (70%) and screening (70% Pap) | Status quo vaccination (70%), switch to HPV screening (70%) | ECC Action Plan goal: 90% vaccination, 90% HPV screening |
|---|---|---|---|---|---|---|
| 2015 | 6.87 | 6.87 | 6.87 | 6.87 | 6.87 | 6.87 |
| 2016 | 6.92 | 6.92 | 6.92 | 6.92 | 6.92 | 6.92 |
| 2017 | 6.74 | 6.74 | 6.74 | 6.74 | 6.74 | 6.74 |
| 2018 | 7.06 | 7.06 | 7.06 | 7.06 | 7.06 | 7.06 |
| 2019 | 6.91 | 6.91 | 6.91 | 6.91 | 6.91 | 6.91 |
| 2020 | 6.66 | 6.66 | 6.66 | 6.66 | 6.66 | 6.66 |
| 2021 | 7.17 | 7.17 | 7.17 | 7.17 | 7.17 | 7.17 |
| 2022 | 6.70 | 6.70 | 6.70 | 6.70 | 6.70 | 6.70 |
| 2023 | 6.36 | 6.36 | 6.36 | 6.36 | 6.36 | 6.36 |
| 2024 | 6.58 | 6.58 | 6.58 | 6.58 | 6.58 | 6.58 |
| 2025 | 6.53 | 6.34 | 6.34 | 6.34 | 6.34 | 6.34 |
| 2026 | 6.05 | 5.98 | 5.98 | 5.98 | 5.98 | 5.98 |
| 2027 | 6.28 | 6.52 | 6.31 | 6.31 | 6.31 | 6.31 |
| 2028 | 5.18 | 5.93 | 5.92 | 5.92 | 5.92 | 5.92 |
| 2029 | 4.84 | 5.69 | 5.91 | 5.74 | 5.74 | 5.74 |
| 2030 | 4.82 | 5.69 | 5.91 | 5.74 | 5.74 | 5.74 |
| 2031 | 4.13 | 4.50 | 5.35 | 5.60 | 5.43 | 5.43 |
| 2032 | 4.16 | 4.41 | 4.70 | 5.43 | 5.37 | 5.37 |
| 2033 | 4.02 | 4.15 | 4.53 | 5.34 | 5.51 | 5.35 |
| 2034 | 3.79 | 3.93 | 4.25 | 4.62 | 5.22 | 5.13 |
| 2035 | 3.65 | 3.79 | 3.88 | 4.27 | 4.98 | 5.11 |
| 2036 | 3.68 | 3.73 | 3.90 | 4.21 | 4.48 | 5.15 |
| 2037 | 3.48 | 3.58 | 3.67 | 3.77 | 4.11 | 4.84 |
| 2038 | 3.46 | 3.48 | 3.54 | 3.70 | 3.96 | 4.24 |
| 2039 | 3.50 | 3.52 | 3.58 | 3.68 | 3.80 | 4.13 |
| 2040 | 3.29 | 3.32 | 3.39 | 3.43 | 3.59 | 3.85 |
| 2041 | 3.16 | 3.21 | 3.23 | 3.29 | 3.40 | 3.53 |
| 2042 | 3.07 | 3.09 | 3.10 | 3.17 | 3.20 | 3.38 |
| 2043 | 3.07 | 3.10 | 3.14 | 3.17 | 3.24 | 3.37 |
| 2044 | 3.03 | 3.07 | 3.10 | 3.11 | 3.14 | 3.17 |
| 2045 | 3.02 | 3.01 | 3.07 | 3.09 | 3.12 | 3.19 |
| 2046 | 3.03 | 3.03 | 3.06 | 3.07 | 3.07 | 3.10 |
| 2047 | 2.85 | 2.90 | 2.89 | 2.94 | 2.97 | 2.98 |
| 2048 | 2.83 | 2.84 | 2.89 | 2.91 | 2.92 | 2.93 |
| 2049 | 2.79 | 2.79 | 2.80 | 2.78 | 2.84 | 2.84 |
| 2050 | 2.80 | 2.82 | 2.82 | 2.82 | 2.80 | 2.81 |
| 2051 | 2.74 | 2.75 | 2.76 | 2.77 | 2.76 | 2.80 |
Oncosim modelling projections were run in 2025 using the World Health Organization’s World Standard Population. Projections assume an HPV vaccination uptake rate of 70 per cent.
*HPV vaccination uptake rates are based on full vaccination against HPV, based on NACI immunization guidelines.
Progress on HPV vaccination in Canada
HPV vaccination rates (one or more doses) by province/territory (years vary)
| Province/Territory* | Year | Vaccination rate** | Category | Additional context |
|---|---|---|---|---|
| British Columbia | 2024 |
Females: 76%
Males: 73%
|
70-79% of 17-year-olds received 1+ dose | The vaccination rates refer to the percentages of people who received at least one dose of HPV vaccination by age 17, by sex. |
| Alberta | 2024 |
Females: 77.4%
Males: 76.9%
|
70-79% of 17-year-olds received 1+ dose | The vaccination rates refer to the percentages of people who received at least one dose of HPV vaccination by age 17, by sex. |
| Saskatchewan | 2018 | Females: 83.8% | 80-89% of 17-year-olds received 1+ dose | The vaccination rate refers to the percentage of females who received at least one dose of HPV vaccination by age 17. |
| Manitoba | 2023 |
Females: 71.4%
Males: 67.1%
|
70-79% of 17-year-olds received 1+ dose | The vaccination rates refer to the percentages of people who received at least one dose of HPV vaccination by age 17, by sex. |
| Ontario | 2023-24 | Overall: 68.0% | ≤69% of 17-year-olds received 1+ dose | The vaccination rate refers to the percentage of people who received at least one dose of HPV vaccination by age 17. |
| Quebec | 2023-24 |
Females: 84.5%
Males: 81.7%
Overall: 83%
|
80-89% of 17-year-olds received 1+ dose | The vaccination rates refer to the percentages of people who received at least one dose of HPV vaccination by age 14, by sex and overall. |
| New Brunswick | 2023-24 |
Females: 70.7%
Males: 65.8%
|
70-79% of 17-year-olds received 1+ dose | The vaccination rates refer to the percentages of people who received at least one dose of HPV vaccination by age 13, by sex. |
| Nova Scotia | 2024 | Overall: 83.4% | 80-89% of 17-year-olds received 1+ dose | The vaccination rate refers to the percentage of people who received at least one dose of HPV vaccination by age 17. |
| Prince Edward Island | 2023-24 |
Overall: 82.6%
|
80-89% of 17-year-olds received 1+ dose | The vaccination rate refers to the percentage of people who received at least one dose of HPV vaccination by age 12. |
| Newfoundland and Labrador | 2019-20 |
Females: 93.4%
Males: 91.4%
Overall: 92.4%
|
≥90% of 17-year-olds received 1+ dose | The vaccination rates refer to the percentages of people who received at least one dose of HPV vaccination by age 12, by sex and overall. |
| Yukon |
Insufficient data
|
Insufficient data | Data not currently available. Efforts are underway in the territories to build analytic capacity and measurement and reporting capabilities. | |
| Northwest Territories |
Insufficient data
|
Insufficient data | Data not currently available. Efforts are underway in the territories to build analytic capacity and measurement and reporting capabilities. | |
| Nunavut |
Insufficient data
|
Insufficient data | Data not currently available. Efforts are underway in the territories to build analytic capacity and measurement and reporting capabilities. |
- All provinces and territories administer GARDASIL®9 on a one-, two- or three-dose schedule according to the National Advisory Committee on Immunization recommended vaccination schedule for HPV vaccines.
- 1-dose HPV vaccination data not available for all jurisdictions. Where not available, 2-dose HPV vaccination rates are reported.
- Jurisdictions are categorized based on the overall vaccination rate. When overall rates are not available, jurisdictions are categorized based on female or male vaccination rate, whichever is higher.
- Each province and territory measures this indicator differently. Because of these differences, data cannot be compared across provinces/territories. Data was gathered from provincial and territorial websites, with the exception of Newfoundland and Labrador, which provided the data directly.
Change in HPV vaccination rates over time (years vary)
| Province/Territory* | Change | Additional context |
|---|---|---|
| British Columbia | Increase |
Age 12: data from the previous period not available.
Age 17: The HPV vaccination rates in 2024 increased compared to 2023.
|
| Alberta | No change |
Age 13: There was no change in the HPV vaccination rates between 2023 and 2024.
Age 17: There was no change in the HPV vaccination rates between 2023 and 2024.
|
| Saskatchewan | Increase |
Age 13: The HPV vaccination rates in 2018 increased compared to 2016.
Age 17 : The HPV vaccination rates in 2018 increased compared to 2016.
|
| Manitoba | Increase |
Age 13: The HPV vaccination rates in 2023 increased compared to 2022.
Age 17: The HPV vaccination rates in 2023 increased compared to 2022.
|
| Ontario | Increase |
Age 12: The HPV vaccination rates in the 2023-24 school increased compared to the 2021-22 school year.
Age 17: Data from the previous period not available.
|
| Quebec | Decrease |
Age 9: There was no change in the HPV vaccination rates between the 2022-23 and 2023-24 school years.
Age 14: The HPV vaccination rates in the 2023-24 school year decreased compared to the 2022-23 school year.
|
| New Brunswick | Decrease | Age 13: The HPV vaccination rates in the 2023-24 school year decreased compared to the 2022-23 school year. |
| Nova Scotia | N/A |
Age 13: The HPV vaccination rates between the 2022-23 and 2023-24 school years cannot be directly compared.
Age 17: The HPV vaccination rates between the 2022-23 and 2023-24 school years cannot be directly compared.
|
| Prince Edward Island | N/A | Data from the previous period not available. |
| Newfoundland and Labrador | N/A | Data from the previous period not available. |
| Yukon | N/A | Data from the previous period not available. |
| Northwest Territories | N/A | Data from the previous period not available. |
| Nunavut | N/A | Data from the previous period not available. |
Change based on at least 1 dose at the given age. Where there were discrepancies between 1 dose and 2 doses, the rate for 1 dose was taken.
Percentage of 14-year old children vaccinated for HPV, by neighbourhood income quintile (before tax), Canada, 2021
| Neighbourhood income quintile | Percent (%) |
|---|---|
| Q1 – lowest | 85.0 |
| Q2 | 80.2 |
| Q3 | 82.3 |
| Q4 | 81.0 |
| Q5 – highest | 89.3 |
Data source: Childhood National Immunization Coverage Survey, Statistics Canada
Percentage of 14-year old children vaccinated for HPV, by location, Canada, 2021
| Location | Percent (%) |
|---|---|
| Rural – very remote | 91.7 |
| Rural – remote | 83.7 |
| Rural | 75.0 |
| Urban | 84.3 |
Data source: Childhood National Immunization Coverage Survey, Statistics Canada
HPV vaccination guidance by province/territory, by dose (2025)
| Province/Territory | Doses |
|---|---|
| British Columbia | 1 |
| Alberta | 2 |
| Saskatchewan | 2 |
| Manitoba | 2 |
| Ontario | 2 |
| Quebec | 1 |
| New Brunswick | 2 |
| Nova Scotia | 1 |
| Prince Edward Island | 2 |
| Newfoundland and Labrador | 2 |
| Yukon | 1 |
| Northwest Territories | 2 |
| Nunavut | 1 |
All provinces and territories administer GARDASIL®9 on a one-, two- or three-dose schedule according to the National Advisory Committee on Immunization recommended vaccination schedule for HPV vaccines.
Immunization coverage for human papillomavirus (HPV) among 12-year olds by number of doses: Ontario 2019-20 to 2023-24 school years
| School year | Doses | Proportion of students (%) |
|---|---|---|
| 2019-2020 | 0 | 19.9 |
| 2020-2021 | 0 | 33 |
| 2021-2022 | 0 | 27.9 |
| 2022-2023 | 0 | 26.5 |
| 2023-2024 | 0 | 32.2 |
| 2019-2020 | 1 | 26.9 |
| 2020-2021 | 1 | 20 |
| 2021-2022 | 1 | 15.4 |
| 2022-2023 | 1 | 9.8 |
| 2023-2024 | 1 | 15.4 |
| 2019-2020 | 2 | 51.5 |
| 2020-2021 | 2 | 46 |
| 2021-2022 | 2 | 56.3 |
| 2022-2023 | 2 | 63.4 |
| 2023-2024 | 2 | 52.3 |
| 2019-2020 | 3 or more | 1.7 |
| 2020-2021 | 3 or more | 1 |
| 2021-2022 | 3 or more | 0.4 |
| 2022-2023 | 3 or more | 0.2 |
| 2023-2024 | 3 or more | 0.1 |
Data source: Public Health Ontario
Current state of cervical screening
Cervical screening coverage and program status
| Jurisdiction | Program status* | Screening coverage (%)** |
|---|---|---|
| British Columbia | Organized population based screening | 65.5 |
| Alberta | Organized population based screening | 74.9 |
| Saskatchewan | Organized population based screening | 74.5 |
| Manitoba | Organized population based screening | 72.6 |
| Ontario | Organized population based screening | 71.0 |
| Quebec | Program announced or planned | 63.4 |
| New Brunswick | Organized population based screening | 64.5 |
| Nova Scotia | Organized population based screening | 61.8 |
| Prince Edward Island | Organized population based screening | 60.4 |
| Newfoundland and Labrador | Organized population based screening | 67.7 |
| Yukon | Opportunistic screening | N/A |
| Northwest Territories | Program announced or planned | N/A |
| Nunavut | Opportunistic screening | N/A |
*Each province and territory provided its program status as of January 2026.
**Age standardized to 2011 Canadian population. Denominator excludes women who have had a hysterectomy. Data source: Statistics Canada. Canadian Community Health Survey
Data source: Statistics Canada. Canadian Community Health Survey
Percentages of women (aged 21-69) reporting at least one Pap test in the past three years, 2017
| Stratification | Classification | Coverage rate (%) |
|---|---|---|
| Immigration status | <10 years | 66.7 |
| Immigration status | ≥10 years | 64.8 |
| Immigration status | Canadian born | 71.1 |
| Location | Urban | 69.0 |
| Location | Rural | 67.6 |
| Age group | 25 to 34 years | 69.6 |
| Age group | 35 to 49 years | 74.7 |
| Age group | 50 to 69 years | 63.4 |
| Indigenous identity* | Indigenous people [2] | 70.5 |
| Indigenous identity* | First Nations people living off reserve | 69.7 |
| Indigenous identity* | Métis | 70.6 |
| Indigenous identity* | Inuit | NA [3] |
| Indigenous identity* | Non-Indigenous (Reference category) | 68.7 |
Age standardized to 2011 Canadian population. Denominator excludes women who have had a hysterectomy.
*New category for 2024
[2] From data notes: “The Indigenous population includes First Nations people living off reserve, Métis and Inuit outside of Inuit Nunangat. Indigenous status is based on the self-reported answer to “Are you First Nations, Métis or Inuk (Inuit)? First Nations (North American Indian) includes Status and Non-Status Indians.””
[3] Suppressed; “too unreliable to be published”
Data source: Statistics Canada. Canadian Community Health Survey
HPV primary screening progress
HPV screening in Canada, 2025
| Jurisdiction | Level of implementation | HPV self-screening level of implementation |
|---|---|---|
| British Columbia | Jurisdiction-wide implementation | Jurisdiction-wide implementation |
| Alberta | Planning for implementation | Pilot |
| Saskatchewan | Planning for implementation | Planning for implementation |
| Manitoba | Planning for implementation | Pilot |
| Ontario | Jurisdiction-wide implementation | Partial implementation |
| Quebec | Partial implementation | Planning for implementation |
| New Brunswick | Planning for implementation | Planning for implementation |
| Nova Scotia | Planning for implementation | Planning for implementation |
| Prince Edward Island | Jurisdiction-wide implementation | Partial implementation |
| Newfoundland and Labrador | Planning for implementation | Planning for implementation |
| Yukon | Planning for implementation | Planning for implementation |
| Northwest Territories* | Partial implementation | Partial implementation |
| Nunavut | Planning for implementation | Planning for implementation |
Each province and territory provided its implementation status as of January 2026.
*HPV primary screening, including HPV self-screening, is offered opportunistically in the Northwest Territories
HPV Positive Screen Follow-Up
Projected colposcopy demand, 2023 to 2053
Description: Colposcopy demand modelling projections using the OncoSim-Cervix tool. Implementation follows an age-based approach (aged >50 first, followed by aged >40, and lastly aged >= 25).
| Year | Age-based transition over 7y to HPV testing every 5y | Age-based transition over 3y to HPV testing every 5y | Immediate transition to HPV testing every 5y | Pap testing every 3y |
|---|---|---|---|---|
| 2023 | 228,413 | 228,413 | 228,413 | 228,413 |
| 2024 | 228,082 | 228,082 | 283,970 | 218,505 |
| 2025 | 214,871 | 226,910 | 294,098 | 205,529 |
| 2026 | 212,674 | 256,232 | 287,664 | 202,594 |
| 2027 | 204,726 | 248,502 | 185,089 | 201,765 |
| 2028 | 184,421 | 202,890 | 84,475 | 198,033 |
| 2029 | 204,409 | 148,703 | 145,072 | 199,433 |
| 2030 | 205,588 | 127,720 | 207,359 | 198,680 |
| 2031 | 173,033 | 162,935 | 213,191 | 194,865 |
| 2032 | 170,163 | 180,014 | 146,367 | 193,906 |
| 2033 | 140,032 | 150,163 | 78,961 | 193,379 |
| 2034 | 120,478 | 115,400 | 119,929 | 188,920 |
| 2035 | 123,717 | 106,276 | 156,689 | 187,671 |
| 2036 | 121,582 | 129,411 | 158,331 | 187,240 |
| 2037 | 128,180 | 138,155 | 112,622 | 186,074 |
| 2038 | 113,155 | 117,417 | 67,987 | 186,126 |
| 2039 | 102,986 | 93,391 | 100,270 | 184,868 |
| 2040 | 104,833 | 92,091 | 129,306 | 182,941 |
| 2041 | 100,173 | 109,994 | 129,669 | 183,686 |
| 2042 | 107,571 | 117,845 | 95,914 | 183,447 |
| 2043 | 98,089 | 100,580 | 62,500 | 182,986 |
| 2044 | 90,279 | 81,050 | 89,881 | 183,557 |
| 2045 | 89,967 | 80,051 | 110,600 | 184,639 |
| 2046 | 85,064 | 94,490 | 109,970 | 184,569 |
| 2047 | 92,247 | 101,875 | 83,839 | 184,093 |
| 2048 | 88,254 | 91,485 | 59,986 | 185,243 |
| 2049 | 82,916 | 75,103 | 82,579 | 185,121 |
| 2050 | 82,515 | 72,400 | 98,628 | 187,127 |
| 2051 | 78,350 | 84,321 | 96,972 | 186,651 |
| 2052 | 83,185 | 90,874 | 76,783 | 185,046 |
| 2053 | 78,185 | 82,189 | 57,428 | 184,944 |